hsd1

11β-HSD1-IN-12 is an 11β-HSD1 inhibitor.11β-HSD1-IN-12 is implicated in the conversion of glucocorticoids in vivo and can be used to study metabolic syndrome and obesity.

11β-HSD1-IN-1 is an inhibitor of 11β-hydroxydehydrogenase 1 (11β-HSD1, IC50: 52 nM) used for the treatment of pain.

11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively. 11β-Hsvd1-in-11 is a compound used as a chemical compound. 11β-HSD1-IN-11 is a hormone involved in regulating various physiological processes, such as metabolism, inflammation, and stress responses. 11β-Hd1-in-11 is a potential compound for the treatment of metabolic disorders, obesity, and certain inflammatory conditions.

11β-HSD1 inibitor 19 shows inhibitory activities for hHSD1 and mHSD1 with IC50s of 16 nM and 10 nM.

AZD8329 is a selective and potent 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that inhibits 11β-HSD2, 17β-HSD1, 17β-HSD3, and can be used for the study of allergic reactions in humans.

HSD-016 is an orally active, selective and potent type 1 11β-hydroxysteroid dehydrogenase (11β-HSD1) inhibitor with strong inhibitory effects on human, mouse and rat 11β-HSD1.HSD-016 can be used in the study of diabetes and metabolic syndrome.

BMS-823778 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) for the study of type 2 diabetes.

Emodin (Frangula emodin) is an 11β-HSD1 inhibitor with a selective IC50 of 186 and 86 nM against 11β-HSD1 in humans and mice, respectively. Emodin has antiviral, anti-inflammatory, and anti-cancer effects. Emodin can improve metabolic disorders in diet-induced obese mice.

Octyl-beta-D-glucopyranoside (11β-HSD1-IN-11) is a non-ionic detergent, it can be widely used in the research of biotechnical, biochemical applications, solubilization and crystallization of membrane proteins.

PBRM (17β-HSD1-IN-2) is a selective covalent inhibitor of 17β-HSD1, used in breast cancer and endometriosis research.

BVT-14225, a selective 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, has an IC50 value of 52 nM.

Metyrapone (NSC-25265) is an inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.

(Rac)-BMS-816336 (Compound 6n), a racemate of BMS-816336, is a potent inhibitor of human and mouse 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with IC50 values of 10 nM and 68 nM, respectively, and demonstrates good metabolic stability [1].

AZD 4017 is an inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) (IC50: 7 nM).

The dose-dependent effect of PF-915275 on the conversion of cortisone to cortisol in primary human and monkey hepatocytes (EC50: 20 and 100 nM, respectively). PF-915275 is an effective and selective human 11β-hydroxysteroid dehydrogenase type 1 inhibitor

BVT 2733 is a new, non-steroidal, isoform-specific inhibitor of 11β-HSD1.

Carbenoxolone (Biogastrone) is an inhibitor of 11β-HSD and gap junction connexin channels. Carbenoxolone inhibits macrophage migration into atria and prevents the development of fatty liver disease.

11Beta-hydroxyprogesterone (11β-Hydroxyprogesterone) is an inhibitor of 11beta-hydroxysteroid dehydrogenase (11betaHSD) type 2, which activates the human hydrocorticosteroid receptor in COS-7 cells, and may be useful in the study of metabolism-related diseases.

PROTAC11β-HSD1 Degrader 1 is an efficient PROTAC that targets 11β-HSD1 (11β-hydroxysteroid dehydrogenase 1). It induces the ubiquitin-proteasome-dependent degradation of 11β-HSD1, and is applicable for research in type 2 diabetes (T2DM).

WAY-311610 is an 11β-hydroxysteroid dehydrogenase HSD11B1 inhibitor that inhibits the 11β-HSD1 enzyme with an IC = 0.34 μM.It can be used to study neuropathic pain, inflammatory pain, and occipital neuralgia.

11β-HSD1 inibitor 17 is an inhibitor of 11β-hydroxysteroid dehydrogenase (11β-HSD1).

11β-HSD1-IN-24 (Compound 10l) is a potent and selective inhibitor of 11β-HSD1 with an IC50 value of 0.5 nM. This compound efficiently blocks the conversion of inactive cortisone to active cortisol and can be utilized in research related to metabolic diseases, such as type 2 diabetes.

11β-HSD1-IN-25 is a selective and orally bioavailable inhibitor of 11β-HSD1. It effectively reduces glucocorticoid levels in vitro and in serum, while also diminishing lipid accumulation in both in vitro and in vivo models. 11β-HSD1-IN-25 modulates lipid metabolism through a dual mechanism: inhibiting 11β-HSD1 and activating the AMP-activated protein kinase (AMPK) signaling pathway. This compound is valuable for research on obesity and related metabolic disorders in vivo.

17β-HSD1-IN-1 (Compound 1) is a highly selective inhibitor of 17β-HSD1 with IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2, and it can be used in non-small cell lung cancer (NSCLC) research [1].